Difference between revisions of "Ondansetron (Zofran)"
m |
m |
||
Line 10: | Line 10: | ||
==Also known as== | ==Also known as== | ||
− | Ondansetron ODT, ondansetron oral solution, ondansetron orally disintegrating tablets, zofran ODT, zofran oral solution, zofran orally disintegrating tablets. | + | Ondansetron HCL, ondansetron ODT, ondansetron oral solution, ondansetron orally disintegrating tablets, zofran HCL, zofran ODT, zofran oral solution, zofran orally disintegrating tablets. |
==References== | ==References== |
Revision as of 16:11, 13 October 2014
General information
Class/mechanism: Selective serotonin 5-HT3 receptor antagonist. Chemotherapy medications can cause nausea and vomiting by stimulating release of serotonin from the enterochromaffin cells of the small intestine, and serotonin triggers the vomiting reflex by binding to and activating 5-HT3 receptors. Ondansetron prevents nausea and vomiting by binding with high affinity to 5-HT3 receptors and blocking their activation by serotonin.[1][2]
Route: PO, IV
Extravasation: no information available
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
Also known as
Ondansetron HCL, ondansetron ODT, ondansetron oral solution, ondansetron orally disintegrating tablets, zofran HCL, zofran ODT, zofran oral solution, zofran orally disintegrating tablets.